解放军医学院学报
解放軍醫學院學報
해방군의학원학보
Academic Journal of Chinese Pla Medical School
2015年
5期
461-465
,共5页
徐玉梅%孟晓丽%王丽强%葛梅%黄一飞
徐玉梅%孟曉麗%王麗彊%葛梅%黃一飛
서옥매%맹효려%왕려강%갈매%황일비
有晶状体眼人工晶状体%植入式接触镜%近视%视力
有晶狀體眼人工晶狀體%植入式接觸鏡%近視%視力
유정상체안인공정상체%식입식접촉경%근시%시력
phakic intraocular lenses%implantable contact lens%myopia%vision
目的：评价有晶体眼后房型人工晶体眼内植入治疗高度近视的临床效果。方法回顾性分析2011年9月-2012年3月于解放军总医院眼科行有晶体眼后房型人工晶体植入的高度近视病例41例共80眼，年龄19~41(27.0±6.2)岁，男15例，女26例，植入晶体均为可植入接触镜(implantable contact lenses，ICL)，分别于术前、术后1 d、1周、1个月、3个月、6个月、12个月进行裸眼视力(uncorrected visual acuity，UCVA)、最佳矫正视力(best corrected visual acuity，BCVA)、等效球镜(manifest refraction spherical equivalent，MRSE)、眼压(intraocular pressure，IOP)、角膜内皮计数(endothelial cell density，ECD)、前房深度(anterior chamber depth，ACD)、自然晶体与人工晶体间距离(拱高)检测。结果术后平均随访(12.3±3.1)个月。术后UCVA均提高，平均较术前提高9行，其中≥0.5和≥1.0者分别为91.3%和71.25%；术后所有患者BCVA≥术前BCVA，平均1.05±0.25，其中45眼(56.3%)提高≥1行，18眼(22.5%)提高≥2行，3眼(3.7%)提高≥3行；手术的有效指数和安全指数分别为1.13±0.33和1.25±0.35。等效球镜由术前-11.62±3.37 D降至术后-0.15±0.96 D，术后等效球镜≤1 D和≤0.5 D者分别为87.5%和63.8%；术后1周内一过性高眼压7眼(8.75%)，6眼药物治疗后稳定，1眼因虹膜孔偏小经YAG激光扩孔控制；术前ECD为(2861±413)个/mm2，术后1个月为(2682±498)个/mm2，差异无统计学意义(P＞0.05)；术前ACD为(3.21±0.25) mm，术后为(2.91±0.30)mm，差异有显著统计学意义(P＜0.01)；术后1个月拱高为(711±354)μm；其中有8眼(10%)术后拱高过高≥1000μm，且在术后3个月内有逐渐降低的趋势，有3眼(3.75%)拱高过低≤200μm；术后1眼(1.25%)出现眩光和光晕。结论 ICL矫正高度近视有效、安全、可预测性好，是一种较为理想的手术方式。
目的：評價有晶體眼後房型人工晶體眼內植入治療高度近視的臨床效果。方法迴顧性分析2011年9月-2012年3月于解放軍總醫院眼科行有晶體眼後房型人工晶體植入的高度近視病例41例共80眼，年齡19~41(27.0±6.2)歲，男15例，女26例，植入晶體均為可植入接觸鏡(implantable contact lenses，ICL)，分彆于術前、術後1 d、1週、1箇月、3箇月、6箇月、12箇月進行裸眼視力(uncorrected visual acuity，UCVA)、最佳矯正視力(best corrected visual acuity，BCVA)、等效毬鏡(manifest refraction spherical equivalent，MRSE)、眼壓(intraocular pressure，IOP)、角膜內皮計數(endothelial cell density，ECD)、前房深度(anterior chamber depth，ACD)、自然晶體與人工晶體間距離(拱高)檢測。結果術後平均隨訪(12.3±3.1)箇月。術後UCVA均提高，平均較術前提高9行，其中≥0.5和≥1.0者分彆為91.3%和71.25%；術後所有患者BCVA≥術前BCVA，平均1.05±0.25，其中45眼(56.3%)提高≥1行，18眼(22.5%)提高≥2行，3眼(3.7%)提高≥3行；手術的有效指數和安全指數分彆為1.13±0.33和1.25±0.35。等效毬鏡由術前-11.62±3.37 D降至術後-0.15±0.96 D，術後等效毬鏡≤1 D和≤0.5 D者分彆為87.5%和63.8%；術後1週內一過性高眼壓7眼(8.75%)，6眼藥物治療後穩定，1眼因虹膜孔偏小經YAG激光擴孔控製；術前ECD為(2861±413)箇/mm2，術後1箇月為(2682±498)箇/mm2，差異無統計學意義(P＞0.05)；術前ACD為(3.21±0.25) mm，術後為(2.91±0.30)mm，差異有顯著統計學意義(P＜0.01)；術後1箇月拱高為(711±354)μm；其中有8眼(10%)術後拱高過高≥1000μm，且在術後3箇月內有逐漸降低的趨勢，有3眼(3.75%)拱高過低≤200μm；術後1眼(1.25%)齣現眩光和光暈。結論 ICL矯正高度近視有效、安全、可預測性好，是一種較為理想的手術方式。
목적：평개유정체안후방형인공정체안내식입치료고도근시적림상효과。방법회고성분석2011년9월-2012년3월우해방군총의원안과행유정체안후방형인공정체식입적고도근시병례41례공80안，년령19~41(27.0±6.2)세，남15례，녀26례，식입정체균위가식입접촉경(implantable contact lenses，ICL)，분별우술전、술후1 d、1주、1개월、3개월、6개월、12개월진행라안시력(uncorrected visual acuity，UCVA)、최가교정시력(best corrected visual acuity，BCVA)、등효구경(manifest refraction spherical equivalent，MRSE)、안압(intraocular pressure，IOP)、각막내피계수(endothelial cell density，ECD)、전방심도(anterior chamber depth，ACD)、자연정체여인공정체간거리(공고)검측。결과술후평균수방(12.3±3.1)개월。술후UCVA균제고，평균교술전제고9행，기중≥0.5화≥1.0자분별위91.3%화71.25%；술후소유환자BCVA≥술전BCVA，평균1.05±0.25，기중45안(56.3%)제고≥1행，18안(22.5%)제고≥2행，3안(3.7%)제고≥3행；수술적유효지수화안전지수분별위1.13±0.33화1.25±0.35。등효구경유술전-11.62±3.37 D강지술후-0.15±0.96 D，술후등효구경≤1 D화≤0.5 D자분별위87.5%화63.8%；술후1주내일과성고안압7안(8.75%)，6안약물치료후은정，1안인홍막공편소경YAG격광확공공제；술전ECD위(2861±413)개/mm2，술후1개월위(2682±498)개/mm2，차이무통계학의의(P＞0.05)；술전ACD위(3.21±0.25) mm，술후위(2.91±0.30)mm，차이유현저통계학의의(P＜0.01)；술후1개월공고위(711±354)μm；기중유8안(10%)술후공고과고≥1000μm，차재술후3개월내유축점강저적추세，유3안(3.75%)공고과저≤200μm；술후1안(1.25%)출현현광화광훈。결론 ICL교정고도근시유효、안전、가예측성호，시일충교위이상적수술방식。
Objective To evaluate the clinical efficacy of surgical correction for high myopia using phakic intraocular lens.Methods Clinical data about 80 eyes of 41 patients who had implantation of implantable contact lenses (ICL) for the correction of high myopia in Chinese PLA General Hospital from September 2011 to march2012 were retrospectively analyzed. There were 15 males and 26 females with the average age of (27.0±6.2) years old (range: 19-41 years old). The uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), manifest refraction spherical equivalent (MRSE), intraocular pressure (IOP), endothelial cell density (ECD), anterior chamber depth (ACD), space between crystalline lens and intraocular lens (vault) were tested and recorded preoperatively and followed at different time points postoperatively.Results The mean follow-up time was 12.3±3.1 months. Postoperative UCVA were improved in all eyes by 9 lines in snellen chart, with 91.3%≥0.5 and 71.25%≥1.0. BCVA were maintained or improved in all eyes, with 56.3% (45/80) improved by 1 line, 22.5% (18/80) by 2 lines, 3.7% (3/80) by 3 lines. The surgery efficacy index and safety index were 1.13±0.33 and 1.25±0.35, respectively. The mean MRSE was -11.62±3.37 D preoperatively and -0.15±0.96 D postoperatively, 68 eyes (87.5%) were within 1D of emmetropia, 51 eyes (63.8%) were within 0.5 D of emmetropia. Transient IOP elevation occurred in 7 eyes (8.75%) within 1 week postoperatively and stabilized after proper management. ECD was 2 861±413 /mm2 preoperatively and 2 682±498 /mm2 postoperatively, which showed no statistically significant difference (P>0.05). ACD was 3.21±0.25 mm preoperatively and 2.91±0.30 mm postoperatively, which showed statistically significant difference (P<0.01). The mean vault 1 month postoperatively was 711 +/- 354 μm with 8 eyes (10%)≥1 000 μm and 3 eyes (3.75%)≤200 μm. One eye (1.25%) reported glare and halo postoperatively.ConclusionICL implantation for the correction of high myopia is effective, safe and predictable.
